Immunovia AB (publ)
IMMVF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -88.1% | -35.3% | -69.5% | – |
| Cost of Goods Sold | $0 | $2 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 607.8% | 100% | 100% | 100% |
| R&D Expenses | $0 | $1 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $20 | $17 | $29 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $25 | -$0 | $2 | $1 |
| Operating Expenses | $25 | $20 | $19 | $31 |
| Operating Income | -$25 | -$20 | -$19 | -$30 |
| % Margin | -234,230.9% | -22,280% | -13,601.4% | -6,619.6% |
| Other Income/Exp. Net | -$5 | -$21 | -$39 | $33 |
| Pre-Tax Income | -$30 | -$41 | -$58 | $3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$41 | -$58 | $3 |
| % Margin | -29,452% | -45,612.2% | -41,577% | 674.7% |
| EPS | -0.008 | -0.14 | -0.24 | 0.048 |
| % Growth | 94.1% | 41.7% | -599% | – |
| EPS Diluted | -0.008 | -0.14 | -0.24 | 0.048 |
| Weighted Avg Shares Out | 383 | 298 | 241 | 64 |
| Weighted Avg Shares Out Dil | 383 | 298 | 241 | 64 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $33 |
| Interest Expense | $5 | $21 | $39 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | -$3 | -$20 | -$18 | $4 |
| % Margin | -24,348.6% | -21,908.9% | -12,950.4% | 960.4% |